In ER+ breast cancer cell lines, CDK9 targeting has been shown to reduce the level of MYC and MYB expression and E2-independent tumor cell proliferation (21, 22) but little information is available of the effectiveness of CDK9 inhibition in reducing tumor growth in vivo. This evidence concerns the gene CDK9 and neoplasm.